All updates
All updates
today 45JAMA评分4141 JAMA评分1818 Tucidinostat Plus R-CHOP for Large B-Cell Lymphoma—Reply
JAMA精选评分6161 Tucidinostat Plus R-CHOP for Large B-Cell Lymphoma
JAMA精选评分5252 Error in Results
BioPharma Dive精选评分5353 First Tracks climbs on ‘impressive’ celiac study data
BioSpace评分6767 BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival
中文产业新闻Chinese source评分7070 WCLC更新芦康沙妥珠单抗两项晚期NSCLC数据：覆盖少见驱动基因与EGFR高肿瘤负荷人群
中文产业新闻Chinese source评分6060 阿斯利康efzimfotase alfa治疗低磷酸酯酶症III期HICKORY试验未达主要终点
STAT News评分3030 STAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and more
顶刊论文（社媒热度）精选评分6565 Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial.
BioSpace精选评分5050 Syndax ends fibrosis program for Niktimvo after mid-stage disappointment
中文产业新闻精选Chinese source评分7373 百时美施贵宝 RYZ101 三期 ACTION-1 治疗 GEP-NETs 达 PFS 主要终点
中文产业新闻精选Chinese source评分8484 EPCORE DLBCL-2 III期：艾可瑞妥单抗联合R-CHOP显著改善初治DLBCL患者PFS
中文产业新闻Chinese source评分7070 BMS核药RYZ101三期ACTION-1研究达PFS主要终点，市值盘前涨超400亿元
STAT News精选评分5656 STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug
监管与产业动态评分3939 Trio of celiac trial successes puts dosing in the spotlight
中文产业新闻Chinese source评分6262 BMS/RayzeBio RYZ101（²²⁵Ac-DOTATATE）3 期 ACTION-1 试验达到主要终点
中文产业新闻精选Chinese source评分7373 翰森制药HS-10380治疗急性精神分裂症2b期达到主要终点
监管与产业动态评分2828 Merck’s deeper dive into efficacy, safety of $1.3B eye disease drug raises fears of ‘limited’ potential - Fierce Biotech
监管与产业动态评分3030 BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth - Fierce Biotech
监管与产业动态评分1818 Par Health recalls more IV bags over cellulose risk weeks after similar action - Fierce Pharma
监管与产业动态评分3838 Tortugas’ schizophrenia drug proves worth in phase 2 Hansoh trial in China - Fierce Biotech
中文产业新闻Chinese source评分6161 admilparant 60 mg 达主要终点，120 mg 组未显著且 BMS 股价转跌
中文产业新闻Chinese source评分5858 胃肠胰神经内分泌瘤：锕-225 放射配体疗法 RYZ101 三期达标，顶线未披露效应量
中文产业新闻Chinese source评分5858 FDA因4例治疗组死亡暂停evenamide III期ENIGMA-TRS 2研究美国中心入组
medRxiv Oncology精选评分4141 FORESEE: A prospective feasibility trial of functional precision oncology for metastatic breast cancer patients
监管与产业动态评分2020 Signal or noise? > Nuevocor Doses First Patient in Phase 1/2 Gene Therapy Trial for Inherited Cardiomyopathy - BioPharma APAC >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #biotech #competitivemarketing
顶刊论文（社媒热度）精选评分5858 Optogenetic Therapy for Restoring Aspects of Visual Function.
BioPharma Dive精选评分5353 First Tracks climbs on ‘impressive’ celiac study data
临床试验登记精选评分3535 Study of ORJ-001 for the Treatment of IPF
临床试验登记精选评分3535 Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets
监管与产业动态精选评分3737 Comparative efficacy of topical garlic extract and 20% podophyllin solution in the treatment of female genital warts: a triple-blind randomized clinical trial
BioPharma Dive评分6666 Bristol Myers dips on ‘confounding’ lung drug results
BioSpace精选评分6868 BMS’ Phase 3 win for lung drug clouded by high-dose miss
BioSpace精选评分6969 BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win
BioSpace精选评分6969 RevMed's Rasonque gets a subtype data asterisk, but analysts remain bullish
中文产业新闻精选Chinese source评分6060 伏美替尼一线治疗 EGFR exon20ins 非鳞 NSCLC 全球 III 期 FURVENT 未达 PFS 主要终点
中文产业新闻精选Chinese source评分6767 mRNA肿瘤疫苗三期读出阳性，拐点上的三个变量
中文产业新闻精选Chinese source评分6060 阿斯利康ALXN1850低磷酸酯酶症三期临床失败
中文产业新闻精选Chinese source评分7878 信达生物替妥尤单抗N01注射液非活动性甲状腺眼病Ⅲ期阳性，眼球突出应答率达60.4%